Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Preclinical Imaging in Targeted Cancer Therapies.

Iommelli F, De Rosa V, Terlizzi C, Fonti R, Del Vecchio S.

Semin Nucl Med. 2019 Sep;49(5):369-381. doi: 10.1053/j.semnuclmed.2019.06.003. Epub 2019 Jun 19. Review.

PMID:
31470932
2.

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.

De Rosa V, Monti M, Terlizzi C, Fonti R, Del Vecchio S, Iommelli F.

Int J Mol Sci. 2019 Jun 27;20(13). pii: E3134. doi: 10.3390/ijms20133134.

3.

Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins.

Monti M, De Rosa V, Iommelli F, Carriero MV, Terlizzi C, Camerlingo R, Belli S, Fonti R, Di Minno G, Del Vecchio S.

Int J Mol Sci. 2018 Aug 9;19(8). pii: E2350. doi: 10.3390/ijms19082350.

4.

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by 18F-fluorothymidine.

Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S.

Clin Cancer Res. 2018 Jul 1;24(13):3126-3136. doi: 10.1158/1078-0432.CCR-17-3657. Epub 2018 Apr 4.

5.

Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells.

Monti M, Iommelli F, De Rosa V, Carriero MV, Miceli R, Camerlingo R, Di Minno G, Del Vecchio S.

PLoS One. 2017 Feb 6;12(2):e0171362. doi: 10.1371/journal.pone.0171362. eCollection 2017.

6.

Preclinical imaging in oncology: advances and perspectives.

Iommelli F, DE Rosa V, Terlizzi C, Del Vecchio S.

Q J Nucl Med Mol Imaging. 2017 Mar;61(1):33-47. doi: 10.23736/S1824-4785.16.02949-6. Epub 2016 Nov 18. Review.

7.
8.

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.

De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S.

Clin Cancer Res. 2015 Nov 15;21(22):5110-20. doi: 10.1158/1078-0432.CCR-15-0375. Epub 2015 Jul 27.

9.

Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.

Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S.

Clin Cancer Res. 2014 Sep 15;20(18):4806-15. doi: 10.1158/1078-0432.CCR-14-0264. Epub 2014 Jul 22.

10.

Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.

Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.

Breast Cancer Res. 2014 May 5;16(3):R45. doi: 10.1186/bcr3650.

11.

3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S.

J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.

12.

PET/CT in cancer research: from preclinical to clinical applications.

Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M.

Contrast Media Mol Imaging. 2010 Jul-Aug;5(4):190-200. doi: 10.1002/cmmi.368. Review.

PMID:
20812287
13.

Molecular imaging of tumor microenvironment: challenges and perspectives.

Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M.

Q J Nucl Med Mol Imaging. 2010 Jun;54(3):249-58. Review.

PMID:
20639812
14.

Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).

Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M.

Clin Cancer Res. 2009 Aug 15;15(16):5224-33. doi: 10.1158/1078-0432.CCR-08-3270. Epub 2009 Aug 11.

15.

Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.

Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S.

Clin Cancer Res. 2008 Aug 15;14(16):5209-19. doi: 10.1158/1078-0432.CCR-08-0374.

16.

Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior.

Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M.

J Med Chem. 2006 Jun 1;49(11):3416-20.

PMID:
16722662

Supplemental Content

Loading ...
Support Center